Noble Financial Positive on Peregrine Pharma (PPHN) Following Q4 Report; Says Contract Manufacturing to Drive Revs
Tweet Send to a Friend
Noble Financial affirms Peregrine Pharma (Nasdaq: PPHM) witha Buy rating and $1.50 price target after the company announced Q4 and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
